Which brings us to the next question
PlexusDx Weight Management Protocols offer semaglutide and tirzepatide pathways with separate pricing published on the relevant product pages
This triggers the development of malignant tumors in different tissues, for example, the colorectal, liver, or breast cancer [8,9,10], creating a medical triad consisting of overweight, DM, and oncogenesis

How the cagrilintide + tirzepatide stack compares Feature Components Cagrilintide + Tirzepatide Cagrilintide + Tirzepatide CagriSema (Cag + Sema) Cagrilintide + Semaglutide Cagrilintide + Retatrutide Cagrilintide + Retatrutide Feature Receptor coverage Cagrilintide + Tirzepatide AMY + GLP-1R + GIPR (3 families) CagriSema (Cag + Sema) AMY + GLP-1R (2 families) Cagrilintide + Retatrutide AMY + GLP-1R + GIPR + GCGR (4 families) Feature Combination clinical data Cagrilintide + Tirzepatide Preclinical only (Valdecantos 2024) CagriSema (Cag + Sema) Phase 3 REDEFINE-1: ~22.7% at 68 weeks Cagrilintide + Retatrutide None (fully speculative) Feature Best monotherapy result Cagrilintide + Tirzepatide Tirzepatide: 25.5% at 84 weeks CagriSema (Cag + Sema) Semaglutide: ~14.9% at 68 weeks Cagrilintide + Retatrutide Retatrutide: 28.7% at 68 weeks Feature GIP receptor Cagrilintide + Tirzepatide Yes (tirzepatide) CagriSema (Cag + Sema) No Cagrilintide + Retatrutide Yes (retatrutide) Feature Glucagon receptor Cagrilintide + Tirzepatide No CagriSema (Cag + Sema) No Cagrilintide + Retatrutide Yes (retatrutide) Feature Dysesthesia risk Cagrilintide + Tirzepatide No CagriSema (Cag + Sema) No Cagrilintide + Retatrutide Yes (retatrutide) Feature FDA-approved component Cagrilintide + Tirzepatide Yes (tirzepatide as Mounjaro / Zepbound) CagriSema (Cag + Sema) Semaglutide approved

Early clinical trials evaluating the efficacy of GLP-1 receptor agonists reported a slightly increased risk of acute pancreatitis with these medications versus placebo or conventional treatment